Skip to main content

Cost at Issue for New Cholesterol Fighting Drugs

Two drugs that were approved by the FDA last summer have been rejected in large numbers by Express Scripts, the largest pharmacy benefits manager in the U.S., which says many patients do not qualify for the drugs.

Republish
Lead image for this article

Two drugs that were approved by the FDA last summer have been rejected in large numbers by Express Scripts, the largest pharmacy benefits manager in the U.S., which says many patients do not qualify for the drugs. The drugs belong to a new class of medicines called PCSK9 inhibitors that can dramatically reduce LDL cholesterol and are aimed at patients with hereditary forms of high cholesterol or those with cardiovascular disease. (Reuters)

Texans need truth. Help us report it.

Independent Texas reporting needs your support. The Texas Tribune delivers fact-based journalism for Texans, by Texans — and our community of members, the readers who donate, make our work possible. Help us bring you and millions of others in-depth news and information. Will you support our nonprofit newsroom with a donation of any amount?

Support independent Texas news

Become a member. Join today.

Choose an amount or learn more about membership.

$20 $25 $50 Other
Donate now

Information about the authors

Madlin Mekelburg’s staff photo

Learn about The Texas Tribune’s policies, including our partnership with The Trust Project to increase transparency in news.

Explore related story topics